Strensiq Injection

asfotase alfa
18mg/0.45ml(40 mg/ml)
ALEXION EUROPE SAS,
Pack size 12 Glass Vials
Dispensing mode POM
Source FRANCE
AgentTAIBA AL KHALEEJ STORE
Retail Price 67775.50 AED

Indications

Strensiq Injection is used for: Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of asfotase alfa :

Mechanism of Action

HPP is caused by a deficiency in TNSALP (tissue non-specific alkaline phosphatase) enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon Asfotase alfa treatment reduces the enzyme substrate levels.

Note

Strensiq 18mg/0.45ml(40 mg/ml) Injection manufactured by ALEXION EUROPE SAS, . Its generic name is asfotase alfa. Strensiq is availble in United Arab Emirates. Farmaco UAE drug index information on Strensiq Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of asfotase alfa :